In this week’s VJOncology podcast, we explore the latest developments in neuro-oncology, including emerging approaches in immunotherapy, PARP inhibition, and radioligand therapy. Join Nicholas Blondin and Sylvia Kurz of Yale University School of Medicine, New Haven, CT, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Tolga Tuncer of the University of Kansas Medical Center, Kansas, KC, and Dinu Stefan of François Baclese Cancer Center, Caen, France, as they discuss key ASCO findings, including the MAGMA and ROADS trials, lutetium-177 dotatate in meningioma, the molecular landscape of MTAP deletions, neoantigen-specific T-cell therapy for glioblastoma, and intermittent olaparib combined with radiotherapy and temozolomide in high-grade gliomas.